Literature DB >> 33562516

TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers.

Veronika Weyerer1, Markus Eckstein1, Pamela L Strissel1,2, Adrian Wullweber1, Fabienne Lange1, Lars Tögel1, Carol I Geppert1, Danijel Sikic3, Helge Taubert3, Sven Wach3, Bernd Wullich3, Arndt Hartmann1, Robert Stoehr1, Johannes Giedl1.   

Abstract

BACKGROUND: Multifocal occurrence is a main characteristic of urothelial bladder cancer (UBC). Whether urothelial transformation is caused by monoclonal events within the urothelium, or by polyclonal unrelated events resulting in several tumor clones is still under debate. TERT promoter mutations are the most common somatic alteration identified in UBC. In this study, we analyzed different histological tissues from whole-organ mapping bladder cancer specimens to reveal TERT mutational status, as well as to discern how tumors develop.
METHODS: Up to 23 tissues from nine whole-organ mapping bladder tumor specimens, were tested for TERT promoter mutations including tumor associated normal urothelium, non-invasive urothelial lesions (hyperplasia, dysplasia, metaplasia), carcinoma in situ (CIS) and different areas of muscle invasive bladder cancers (MIBC). The mutational DNA hotspot region within the TERT promoter was analyzed by SNaPshot analysis including three hot spot regions (-57, -124 or -146). Telomere length was measured by the Relative Human Telomere Length Quantification qPCR Assay Kit.
RESULTS: TERT promoter mutations were identified in tumor associated normal urothelium as well as non-invasive urothelial lesions, CIS and MIBC. Analysis of separate regions of the MIBC showed 100% concordance of TERT promoter mutations within a respective whole-organ bladder specimen. Polyclonal events were observed in five out of nine whole-organ mapping bladder cancers housing tumor associated normal urothelium, non-invasive urothelial lesions and CIS where different TERT promoter mutations were found compared to MIBC. The remaining four whole-organ mapping bladders were monoclonal for TERT mutations. No significant differences of telomere length were observed.
CONCLUSIONS: Examining multiple whole-organ mapping bladders we conclude that TERT promoter mutations may be an early step in bladder cancer carcinogenesis as supported by TERT mutations detected in tumor associated normal urothelium as well as non-invasive urothelial lesions. Since mutated TERT promoter regions within non-invasive urothelial lesions are not sufficient alone for the establishment of cancerous growth, this points to the contribution of other gene mutations as a requirement for tumor development.

Entities:  

Keywords:  TERT promoter mutation; clonality; whole-organ mapping bladder tumor

Mesh:

Substances:

Year:  2021        PMID: 33562516      PMCID: PMC7915609          DOI: 10.3390/genes12020230

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  18 in total

1.  Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.

Authors:  Sumit Borah; Linghe Xi; Arthur J Zaug; Natasha M Powell; Garrett M Dancik; Scott B Cohen; James C Costello; Dan Theodorescu; Thomas R Cech
Journal:  Science       Date:  2015-02-05       Impact factor: 47.728

2.  Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Authors:  Carolyn D Hurst; Fiona M Platt; Margaret A Knowles
Journal:  Eur Urol       Date:  2013-09-03       Impact factor: 20.096

Review 3.  Origins of Bladder Cancer.

Authors:  Bogdan Czerniak; Colin Dinney; David McConkey
Journal:  Annu Rev Pathol       Date:  2016-02-22       Impact factor: 23.472

4.  Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types.

Authors:  A Kilian; D D Bowtell; H E Abud; G R Hime; D J Venter; P K Keese; E L Duncan; R R Reddel; R A Jefferson
Journal:  Hum Mol Genet       Date:  1997-11       Impact factor: 6.150

5.  Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.

Authors:  Sebastian Stasik; Karsten Salomo; Ulrike Heberling; Michael Froehner; Ulrich Sommer; Gustavo B Baretton; Gerhard Ehninger; Manfred P Wirth; Christian Thiede; Susanne Fuessel
Journal:  Clin Biochem       Date:  2018-12-04       Impact factor: 3.281

6.  TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.

Authors:  Simone Bertz; Robert Stöhr; Nadine T Gaisa; Bernd Wullich; Arndt Hartmann; Abbas Agaimy
Journal:  Histopathology       Date:  2020-07-09       Impact factor: 5.087

Review 7.  Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies.

Authors:  Christian Hafner; Ruth Knuechel; Robert Stoehr; Arndt Hartmann
Journal:  Int J Cancer       Date:  2002-09-01       Impact factor: 7.396

Review 8.  Telomeres: history, health, and hallmarks of aging.

Authors:  Deepavali Chakravarti; Kyle A LaBella; Ronald A DePinho
Journal:  Cell       Date:  2021-01-14       Impact factor: 41.582

9.  Identification of neutral tumor evolution across cancer types.

Authors:  Marc J Williams; Benjamin Werner; Chris P Barnes; Trevor A Graham; Andrea Sottoriva
Journal:  Nat Genet       Date:  2016-01-18       Impact factor: 38.330

10.  TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.

Authors:  Yujiro Hayashi; Kazutoshi Fujita; Satoshi Nojima; Eisuke Tomiyama; Makoto Matsushita; Yoko Koh; Kosuke Nakano; Cong Wang; Yu Ishizuya; Taigo Kato; Koji Hatano; Atsunari Kawashima; Takeshi Ujike; Motohide Uemura; Ryoichi Imamura; Eiichi Morii; Norio Nonomura
Journal:  Mol Oncol       Date:  2020-06-27       Impact factor: 6.603

View more
  1 in total

1.  Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.

Authors:  Veronika Weyerer; Robert Stoehr; Simone Bertz; Fabienne Lange; Carol I Geppert; Sven Wach; Helge Taubert; Danijel Sikic; Bernd Wullich; Arndt Hartmann; Markus Eckstein
Journal:  World J Urol       Date:  2021-07-14       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.